A Phase 4 interventional study of Endovascular treatment using self expandable nitinol STENTS and Open repair treatment in Atherosclerotic Lesions of the Common Femoral Artery, sponsored by Nantes University Hospital. Completed at 17 sites in France. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Nantes University Hospital · Phase 4, Interventional, and Treatment
Even though the indication for endovascular therapy has been enlarged, open repair of common femoral artery is still considered as the treatment of choice. A recent pilot study showed that endovascular repair of the CFA seems to be a safe technique of revascularization with acceptable initial results at 12 months (Azema et al, Eur J Vasc Endovasc Surg, 2011, in press). TECCO, a French randomized and controlled trial, has been set up to compare open and endovascular procedures for the treatment of CFA atherosclerotic lesions.
Nantes University Hospital is the lead sponsor of 825 studies on the registry; 195 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Endovascular treatment using self expandable nitinol STENTS
Device: Open repair treatment
A direct stenting will be performed.
The surgeon will perform its usual technique to revascularize the common femoral artery
Morbid-mortality rate at 30 days
Morbid-mortality rate is defined by: Death, general complications and local complications requiring re-admission and / or reoperation.
Time frame: 30 days
Technical success
Time frame: 1 month
Hospital length of stay
Time frame: 1 month
Primary sustained clinical improvement
Time frame: 1 month
Primary sustained clinical improvement
Time frame: 6 months
Primary sustained clinical improvement
Time frame: 12 months
Primary sustained clinical improvement
Time frame: 24 months
Target lesion revascularization
Time frame: 1 month
Target lesion revascularization
Time frame: 6 months
Target lesion revascularization
Time frame: 12 months
Target lesion revascularization
Time frame: 24 months
In-stent restenosis
Time frame: 1 month
In-stent restenosis
Time frame: 6 months
In-stent restenosis
Time frame: 12 months
In-stent restenosis
Time frame: 24 months
Stent fracture
Time frame: 1 month
Stent fracture
Time frame: 6 months
Stent fracture
Time frame: 12 months
Stent fracture
Time frame: 24 months
Secondary sustained clinical improvement
Time frame: 1 month
Secondary sustained clinical improvement
Time frame: 6 months
Secondary sustained clinical improvement
Time frame: 12 months
Secondary sustained clinical improvement
Time frame: 24 months
Target extremity revascularization
Time frame: 1 month
Target extremity revascularization
Time frame: 6 months
Target extremity revascularization
Time frame: 12 months
Target extremity revascularization
Time frame: 24 months
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nantes University Hospital